Outcomes of daratumumab, pomalidomide, and dexamethasone (DPd) followed by high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) in patients with relapsed/refractory multiple myeloma RRMM

The number of therapeutic options for patients with RRMM has increased significantly. We treated 18 patients with RRMM with DPd as salvage therapy followed by HDCT/ASCT. The ORR after salvage treatment with DPd was 100%. ORR on day 100 post-ASCT was 100%, 67% achieved ≥CR. There was no reported treatment-related mortality on day 100. The 2-year PFS and 2- year OS rate were 83.3% ad 94.4%, respectively
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research